A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Celgosivir; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Apr 2010 Additional lead trial centre and trial investigator identified as reported by ClinicalTrials.gov.
- 11 May 2007 Results have been presented.
- 31 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History